Genzyme's Gene Therapy IP Land Grab
By acquiring Cell Genesys Inc. in a $350 million stock swap, Genzyme Corp. hopes it has found a way to hedge one set of development risks--including potential generic competition for its biggest product, while at the same time doubling up on a technology bet in another area.
You may also be interested in...
Despite the millions of dollars from public initiatives, particularly in California, to fund stem-cell research, VCs will still probably stay away until Big Pharma and Big Biotech show more of their own R&D interest in the area.
Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.